Is avatrombopag included in medical insurance?

Avatrombopag, a drug whose name has become increasingly well-known in recent years, may become a new hope for treatment, especially for patients with specific thrombocytopenia. Avatrombopag is an orally bioavailable small molecule TPO receptor agonist, and its unique therapeutic mechanism has attracted widespread attention in the medical community.

First, we need to clarify the main treatment targets of avatrombopag. It is particularly useful in those patients with thrombocytopenia associated with chronic liver disease. When patients with chronic liver disease are at high risk of bleeding during surgery or invasive procedures due to thrombocytopenia, avatrombopag can significantly increase platelet production by stimulating the proliferation and differentiation of bone marrow megakaryocytes, thereby reducing the risk of bleeding during these procedures.

In addition to thrombocytopenia associated with chronic liver disease, avatrombopag has shown potential in the treatment of other types of thrombocytopenia. For example, it has also been exploratoryly used in the treatment of thrombocytopenia caused by tumor chemotherapy and chronic immune thrombocytopenia. Although these diseases have different causes, they all share the common problem of thrombocytopenia, and avatrombopag is expected to provide new treatment options for these patients through its unique mechanism.

It is important to note that avatrombopag does not restore normal platelet counts in patients with chronic liver disease, but is intended to temporarily increase platelet counts to meet clinical needs in specific situations, such as before surgery or examinations. Therefore, when using this drug, patients need to clearly understand their treatment goals and limitations, and use the drug rationally under the guidance of a doctor.

Avatrombopag has been launched in the country and is included in medical insurance. There are original research or domestic imitation versions available on the market, and the specifications per box are 20mg*15 tablets. After reimbursement, the original research version costs about 4,000 yuan, and the domestic imitation version exceeds 3,000 yuan. It should be noted that overseas imitation versions are cheaper, only about 600 yuan for 28 pieces, and the price difference is huge.

Overall, avatrombopag, as an innovative drug, provides new treatment hope for patients with chronic liver disease-related thrombocytopenia and other thrombocytopenias. Through its unique mechanism of action, it is expected to become an important part of the treatment of thrombocytopenia in the future.